Dr Kelly is suggesting - in his latest musing - an arrangement where NRT sells the package of isoflavinoid technlogy to MEI but retains ownership of the members of the chemical library that are confirmed to not have significant anti-cancer activity, plus first right of refusal to any new chemical entity subsequently identified by MEI that do not have significant anti-cancer activity and they choose not to develop further. NRT could continue researching and developing anti-inflammatory, cardivascular, etc drugs based on these entities. This rather than seeing a 100% ownership whittled down to a 5% interest via a shareholding in MEI diluted because of capital raisings - which more than disappointingly appears to be the sad road NRT management is preparing shareholders for. He thinks MEI will have no interest in looking for anything other than anti-cancer activities. Seems a reasonable way to prevent NRT's most promising asset slipping through our fingers and provide shareholders with a chance to recover their investment sometime down the road. Why didn't NRT management provide shareholders with some encouragement at the AGM that arrangements such as this were being pursued?
I note that Dr Kelly see's value in the glucan technology that NRT will retain with further investment.
Is anyone here holding on for a favourable deal to be done?
- Forums
- ASX - By Stock
- dr kelly suggestions re sale to mei
Dr Kelly is suggesting - in his latest musing - an arrangement...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online